Balderton Capital led a $55m Series B round in Lindus Health.

Balderton Capital, a venture capital firm, led a $55m Series B round in Lindus Health, a clinical research organization (CRO) that manages end-to-end clinical trials, with participation from Creandum, Firstminute, Seedcamp, and Visionaries Club. "We're thrilled to partner with Lindus Health in their mission to improve the clinical research ecosystem. In an industry marked by slow growth and fragmentation, their vision for how clinical trials should operate and unwavering commitment to help improve patient outcomes puts them on a completely different playing field than other companies in this space," Suranga Chandratillake, Balderton General Partner.